{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:28:42Z","timestamp":1790958522693,"version":"4.1.0"},"reference-count":19,"publisher":"SLACK, Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychosoc Nurs Ment Health Serv"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Benzodiazepine drugs are controversial because of safety and abuse liability concerns, although they have clinically relevant pharmacological differences. The current article reviews studies pertaining to the pharmacology, safety, and abuse liability of oxazepam. Compared to other benzodiazepine drugs, oxazepam has a favorable safety and abuse liability profile, which may be related to its pharmacology. Oxazepam is more slowly absorbed and enters the brain more slowly than other benzodiazepine drugs; it does not have active metabolites and does not accumulate with chronic dosing; its metabolism is not affected by age or by mild\/moderate liver disease; and it is not prone to drug\u2013drug interactions. Oxazepam also binds to the translocator protein, which stimulates the synthesis of neurosteroids, and this effect may contribute to its reduced abuse liability. [<jats:italic>Journal of Psychosocial Nursing and Mental Health Services, 54<\/jats:italic>(4), 22\u201325.]<\/jats:p>","DOI":"10.3928\/02793695-20160322-01","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T17:56:46Z","timestamp":1461607006000},"page":"22-25","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Abuse Liability of Oxazepam: Is This Benzodiazepine Drug Underutilized?"],"prefix":"10.3928","volume":"54","author":[{"given":"Robert H.","family":"Howland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2016.303061"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6974.219"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244106"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427437"},{"key":"e_1_3_1_6_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0022-3565(25)21979-6","article-title":"Comparison of diazepam and oxazepam: Preference, liking and extent of abuse","volume":"229","author":"Griffiths R.R.","year":"1984","unstructured":"Griffiths R.R., McLeod D.R., Bigelow G.E., Liebson I.A., Roache J.D., Nowowieski P. (1984b). Comparison of diazepam and oxazepam: Preference, liking and extent of abuse. Journal of Pharmacology and Experimental Therapeutics, 229, 501\u2013508.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199008000-00002"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(93)90090-D"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000262"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200110000-00008"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1976.tb03107.x"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2190"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1102927"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6409a1"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.162"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53630-3.00008-7"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2014.06.032"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.163.3.386"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.10.041"},{"key":"e_1_3_1_20_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0026-895X(25)14965-1","article-title":"Structural requirements for the binding of benzodiazepines to their peripheral-type sites","volume":"25","author":"Wang J.K.","year":"1984","unstructured":"Wang J.K., Taniguchi T., Spector S. (1984). Structural requirements for the binding of benzodiazepines to their peripheral-type sites. Molecular Pharmacology, 25, 349\u2013351.","journal-title":"Molecular Pharmacology"}],"container-title":["Journal of Psychosocial Nursing and Mental Health Services"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/psychiatry\/journals\/jpn\/2016-4-54-4\/%7Ba68e8335-2103-42db-9e10-a94617a674f3%7D\/safety-and-abuse-liability-of-oxazepam-is-this-benzodiazepine-drug-underutilized","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T21:41:20Z","timestamp":1748900480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/02793695-20160322-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.3928\/02793695-20160322-01"],"URL":"https:\/\/doi.org\/10.3928\/02793695-20160322-01","relation":{},"ISSN":["0279-3695","1938-2413"],"issn-type":[{"value":"0279-3695","type":"print"},{"value":"1938-2413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}